Skip to main content

Table 2 Response rate

From: Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma

Pathology specimens, n

12

Pathologic responses, n (%)

 Complete pathologic response (TRG 0)

3 (25)

 Partial pathologic response

 < 10% viable cells (TRG 1)

3 (25)

 10–50% viable cells (TRG 2)

4 (33.3)

 > 50% viable cells (TRG 3)

2 (16.7)

Pathologic staging, n (%)

 ypT0N0

3 (25)

 ypT2N0

1 (8.3)

 ypT3N0

4 (33.3)

 ypT3N1

2 (16.7)

 ypT3N2

1 (8.3)

 ypT4aN2a

1 (8.3)